Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2014 5
2015 8
2016 3
2017 1
2018 2
2020 4
2021 14
2022 10
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: yagishita s. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia.
Miyazaki B, Ueno T, Sugiyama M, Kojima S, Arakawa A, Tao K, Tanimura K, Shiraishi K, Yagishita S, Kohsaka S, Kato M, Kiyokawa N, Goto Y, Yatabe Y, Hamada A, Mano H, Ogawa C, Tanaka Y. Miyazaki B, et al. Among authors: yagishita s. NPJ Precis Oncol. 2023 Dec 9;7(1):132. doi: 10.1038/s41698-023-00485-7. NPJ Precis Oncol. 2023. PMID: 38071343 Free PMC article.
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: yagishita s. Br J Cancer. 2023 Dec;129(12):2003-2013. doi: 10.1038/s41416-023-02427-3. Epub 2023 Sep 20. Br J Cancer. 2023. PMID: 37731022
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.
Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Katsuya Y, et al. Among authors: yagishita s. Front Oncol. 2023 Jan 9;12:966527. doi: 10.3389/fonc.2022.966527. eCollection 2022. Front Oncol. 2023. PMID: 36698400 Free PMC article.
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma.
Kojima Y, Yoshida H, Okuya T, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Shimoi T, Tamura K, Tanase Y, Uno M, Ishikawa M, Arakaki M, Ichikawa H, Yagishita S, Hamada A, Fujiwara Y, Yonemori K, Kato T. Kojima Y, et al. Among authors: yagishita s. Gynecol Oncol Rep. 2023 Nov 14;50:101302. doi: 10.1016/j.gore.2023.101302. eCollection 2023 Dec. Gynecol Oncol Rep. 2023. PMID: 38054200 Free PMC article.
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
Torasawa M, Horinouchi H, Yagishita S, Utsumi H, Okuda K, Takekoshi D, Ito S, Wakui H, Murata S, Kaku S, Okuma K, Matsumoto Y, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Araya J, Ohe Y, Fujita Y. Torasawa M, et al. Among authors: yagishita s. Thorac Cancer. 2023 Oct;14(29):2909-2923. doi: 10.1111/1759-7714.15077. Epub 2023 Aug 24. Thorac Cancer. 2023. PMID: 37614219 Free PMC article.
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: yagishita s. Br J Cancer. 2023 Dec;129(12):2034. doi: 10.1038/s41416-023-02481-x. Br J Cancer. 2023. PMID: 37923915 Free article. No abstract available.
57 results